Catalog No.
Product Name
Application
Product Information
Citations
-
calcium channel blocker
Isradipine is a calcium channel blocker of the dihydropyridine class.- Deborah A. Goldspink, .et al. , Mol Metab, 2018, Jan; 7: 90-101 PMID: 29167062
-
Selective calcium chelator
BAPTA/AM, an intracellular calcium chelator, induces delayed necrosis by lipoxygenase-mediated free radicals in mouse cortical cultures.- Maohuan Ran, .et al. , Ecotoxicol Environ Saf, 2026, May:316:120163 PMID: 42013791
- Jian Sun, .et al. , Nanoscale, 2024, Dec 17 PMID: 39688368
- Jiunn-Chang Lin, .et al. , Toxicol Appl Pharmacol, 2023, Jul 15;471:116568 PMID: 37245555
- Liying Wu, .et al. , Phytother Res, 2022, Feb;36(2):938-950 PMID: 35076979
- Shichen Xu, .et al. , Cell Signal, 2020, Aug 6;75:109733 PMID: 32771398
- Miho Akimoto, .et al. , Cell Death Dis, 2018, Aug; 9(8): 804 PMID: 30038429
- Zhang L, .et al. , Medicine (Baltimore), 2018, Jun;97(24):e11095 PMID: 29901626
- Manidipine 2HCl is a HCl salt form of Manidipine which is a calcium channel blocker for Ca2+ current with IC50 of 2.6 nM.
- Noriaki Ikemura,, .et al. , Chem -Biol Interact, 2019, 306:1-9 PMID: 30965050
-
Calcium Channel inhibitor
Nimodipine is a L-type Ca2+ channel blocker.- Shiqian Han, .et al. , iScience, 2023, Apr 8;26(5):106613 PMID: 37128603
-
L-type calcium channel blocker
Amlodipin is L-type calcium channel blocker that displays antihypertensive properties. It inhibits Ca2+-induced contractions in depolarized rat aorta (IC50 = 1.9 nM) and displays vasoprotective effects in cardiovascular disease. -
L-type calcium channel blocker
Amlodipine-besylate is L-type calcium channel blocker that displays antihypertensive properties. It inhibits Ca2+-induced contractions in depolarized rat aorta (IC50 = 1.9 nM) and displays vasoprotective effects in cardiovascular disease. -
Calcium channel blocker
Cilnidipine is a dual blocker of L-type voltage-gated calcium channels in vascular smooth muscle and N-type calcium channels in sympathetic nerve terminals that supply. - Diethylstilbestrol is a synthetic nonsteroidal estrogen that was first synthesized in 1938. It is also classified as an endocrine disruptor.
- Diltiazem is a nondihydropyridine (non-DHP) member of the class of drugs known as calcium channel blockers, used in the treatment of hypertension, angina pectoris, and some types of arrhythmia.
- Manidipine is a dihydropyridine compound and calcium channel protein inhibitor and antagonist.
-
calcium channel blocker
Nisoldipine(BAY-k 5552; Sular) is a calcium channel blocker belonging to the dihydropyridines class, specific for L-type Cav1.2 with IC50 of 10 nM. -
Calcium Channel inhibitor
Tetrandrine is a calcium channel blocker. It inhibits the degranulation of mast cells.Tetrandrine has anti-inflammatory and anti-fibrogenic actions, which make tetrandrine and related compounds potentially useful in the treatment of lung silicosis, liver cirrhosis, and rheumatoid arthritis. -
Calcium channel antagonist
Felodipine is a 1,4-dihydropyridine antagonist and calcium channel protein inhibitor.
-
IL-1 Inhibitor
Diacerein is a potent IL-1 inhibitor that functions by reducing the production of IL-1 converting enzyme, thereby inhibiting the activation of IL-1β and its downstream signaling pathways. This compound exhibits significant anti-inflammatory and anti-rheumatic properties, making it useful for various research applications, including studies on osteoarthritis and the management of bronchospasm and airway inflammation in asthmatic models. Diacerein is recognized as a slow-acting drug for symptomatic relief of osteoarthritis, facilitating insights into long-term therapeutic strategies. -
T-type calcium channel Blocker
KTt-45 is a selective T-type calcium channel blocker that exhibits significant anticancer activity. This compound induces apoptosis in the HeLa cervical cancer cell line, making it a valuable tool for studying the mechanisms of cancer cell death. Its ability to modulate calcium signaling has implications for research in cancer therapeutics and cellular physiology. -
SERCA2 Inhibitor
COX-2-IN-55 is a selective SERCA2 inhibitor that exhibits promising anticancer properties, with a unique profile derived from a Celecoxib analog. This compound enhances caspase-3 cleavage and elevates DR5 levels, leading to the activation of GRP78, which contributes to the repression of triple-negative breast cancer (TNBC) progression. Additionally, COX-2-IN-55 reduces angiogenic markers such as VEGF-α and IL-8, effectively inhibiting microvessel formation and supporting its potential utility in cancer research applications. -
Calcium Channel Blocker
14-Deoxyandrographolide is a diterpene known for its calcium channel blocking activity, functioning as a uterine smooth muscle relaxant. It enhances nitric oxide (NO) release in endothelial cells, contributing to vasodilation. Additionally, 14-Deoxyandrographolide modulates liver cell sensitivity to TNF-α mediated apoptosis by promoting the release of TNFRSF1A, making it a valuable compound for research into vascular health and liver cell biology. -
PKA inhibitor
HA-1004 is a selective and multifunctional inhibitor of cyclic nucleotide-dependent protein kinases, including protein kinase A (PKA) and cyclic GMP-dependent protein kinase (PKG). It regulates key second messenger pathways involving cyclic AMP and cyclic GMP and has broad pharmacological effects. HA-1004 inhibits lipolysis and induces vascular smooth muscle relaxation, acting as a vasodilator. It also functions as a calcium antagonist, contributing to its ability to suppress contraction in rabbit aortic strips. In neurological models, HA-1004 has been shown to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models, suggesting potential relevance in addiction and neurochemical regulation. Its diverse actions make it a valuable tool for studying cardiovascular, metabolic, and neurobiological processes. -
Bone resorption inhibitor
Chicken calcitonin is a peptide hormone involved in the regulation of calcium metabolism. It inhibits bone resorption by suppressing the motility and activity of osteoclasts, as demonstrated in neonatal rat models. This hormone plays a key role in maintaining bone homeostasis and is of interest in bone-related research. -
Calcium Channel Blocker
Nitrendipine is a dihydropyridine calcium channel blocker primarily acting on L-type calcium channels. It exhibits significant antihypertensive properties and has been shown to induce apoptosis in various cellular contexts, including neuroblastoma. Additionally, Nitrendipine alleviates withdrawal symptoms associated with alcohol and morphine and reduces right ventricular hypertrophy and pulmonary vascular alterations induced by intermittent hypoxia. Its diverse biological activities make it valuable in research related to cardiovascular health and cancer biology. -
Calcium Channel Blocker
Lercanidipine hydrochloride is a third-generation dihydropyridine calcium channel blocker with a primary mechanism of selectively inhibiting vascular calcium channels. Its potent antihypertensive effects are complemented by reno- and neuro-protective properties, making it valuable for research into cardiovascular and neurological conditions. Additionally, Lercanidipine exhibits anti-oxidant, anti-inflammatory, and anti-apoptotic activities, further supporting its utility in various biomedical applications. -
L-type Calcium Channel Blocker
Fendiline is an L-type calcium channel blocker that exhibits an IC50 of 17 µM. In addition to its role in cardiovascular modulation, Fendiline acts as a selective inhibitor of K-Ras, with an IC50 of 9.64 μM, effectively preventing K-Ras plasma membrane localization and blocking downstream signaling. This compound has demonstrated potential in inhibiting the proliferation of various cancer cell lines such as pancreatic, colon, lung, and endometrial cancers that express oncogenic mutant K-Ras. Furthermore, Fendiline serves as a STING agonist, showing promise in inhibiting the growth of refractory cold tumors, including MC38, CT26, and B16F10. -
Calcium channel blocker
Mibefradil is a calcium channel blocker with moderate selectivity for T-type Ca2+ channels displaying IC50s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively. -
Calcium channel blocker
Mibefradil 2Hcl is calcium channel blocker with moderate selectivity for T-type Ca2+ channels displaying IC50 values of 2.7 uM and 18.6 uM for T-type and L-type channels respectively. - N-type calcium channel blocker-1 is an orally active analgesic agent which shows high affinity to functionally block N-type calcium channels with an IC50 of 0.7 μM in the IMR32 assay.
-
T-type Ca2+ channel blocker
ABT-639 hydrochloride is a novel, peripherally acting, selective T-type Ca2+ channel blocker. - Pinaverium Bromide is a spasmolytic agent with low incidence of anticholinergic effects. Pinaverium Bromide is also an antispasmodic.
-
glutamate release inhibitor
Sipatrigine, a neuroprotective agent, is a glutamate release inhibitor, voltage-dependent sodium channel and calcium channel inhibitor, penetrating the central nervous system. Has potential to treat focal cerebral ischemia and stroke. -
dihydropyridine calcium entry blocker
Lemildipine is a new dihydropyridine calcium entry blocker. -
Calcium channel blocker
Amlodipine aspartic acid impurity is the impurity of Amlodipine aspartic acid. Amlodipine aspartic acid is a calcium channel blocker with antihypertensive and antianginal properties. -
calcium channel blocker
Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence. that attenuates liver fibrosis and may increase antioxidant defence. -
Ca2+ signaling modulator
Astragaloside A is a novel regulator of HIF-1α and angiogenesis through the PI3K/Akt pathway in HUVECs that are exposed to hypoxia. - Benidipine hydrochloride is a long-acting T-type calcium channel blocker, on blood pressure and renal function in hypertensive patients with diabetes mellitus.
-
calcium channel blocker
Nilvadipine is a calcium channel blocker (CCB) used for the treatment of hypertension and chronic major cerebral artery occlusion -
Calcium channel blocker
Clevidipine is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. -
Ca2+ channel agonist/CDK2 inhibitor
Ca2+ channel agonist 1 is an agonist of N-type Ca2+ channel and an inhibitor of Cdk2, with EC50s of 14.23 μM and 3.34 μM, respectively, and is used as a potential treatment for motor nerve terminal dysfunction. - Atagabalin is related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2).
- CRAC intermediate 2 is a intermediate compound for CRAC inhibitor synthesis, extracted from patent WO 2013059666A1.
-
Ca2+ release inhibitor
Dantrolene sodium is a muscle relaxant that acts by abolishing excitation-contraction coupling in muscle cells, probably by action on the ryanodine receptor. -
Selective calcium chelator
BAPTA tetrapotassium is a selective calcium chelator with greater affinity for Ca2+ than Mg2+. -
SERCA inhibitor
Cyclopiazonic acid is an inhibitor of SERCA (endoplasmic reticulum Ca2+-ATPase) which induces the release of intracellular stored Ca2+, without increasing IP3 levels. -
Calcium channel blocker
Efonidipine is a dihydropyridine calcium channel blocker that blocks both T-type and L-type calcium channels. It has also been studied in atherosclerosis and acute renal failure.
